Ad
related to: median progression-free survival
Search results
Results From The WOW.Com Content Network
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
[medical citation needed] While overall survival in this trial is not yet known, response rates at second line were 91.7% in sensitive disease with median progression-free survival of 5.8 months, and; 33.3% in resistant disease with median progression-free of 3.5 months. [18] [19]
Durvalumab increased the median progression-free survival from 5.6 months (placebo) to 16.8 months (durvalumab); the 12 month progression-free survival rate was increased from 35.3% (placebo) to 55.9% (durvalumab), and the 18 month progression-free survival rate was increased from 27.0% (placebo) to 44.2% (durvalumab). [10]
In a clinical trial of 50 patients, combination of olaparib and temozolomide in relapsed small-cell lung cancer yielded an overall response rate of 41.7%, median progression-free survival 4.2 months, and overall survival was 8.5 months. [65] Lurbinectedin showed increased overall survival rate in relapsed small cell lung cancer in a trial. [66]
In a phase III study, median progression-free survival was significantly longer in the sunitinib group (11 months) than in the IFNα group (five months), with a hazard ratio of 0.42. [2] [10] In the secondary endpoints, 28% had significant tumor shrinkage with sunitinib compared to 5% with IFNα. Patients receiving sunitinib had a better ...
This new designation resulted from the ASCEND-4 clinical trial, which was a randomized, phase III study that compared the use of ceritinib to standard-of-care platinum-based chemotherapy treatments. Median progression-free survival was 16.6 months for ceritinib (n=189) versus 8.1 months in the chemotherapy-treated patients (n=187). [16]
After a median follow-up of 52 months, the median progression free and overall survival times were 41 months and 55 months, respectively; 3- and 5-year progression-free rates were 52% and 43%, respectively; and 3- and 5-year overall survival rates were 60% and 49%, respectively.
The study met its primary efficacy endpoint with a median increase in progression-free survival (PFS) from 3.6 months to 5.6 months in the pooled patients treated with TH-302 (at 240 mg/m2 or 340 mg/m2) in combination with gemcitabine compared to gemcitabine alone.